GPM Growth Investors Inc. Sells 184 Shares of Stryker Co. (NYSE:SYK)

GPM Growth Investors Inc. decreased its position in Stryker Co. (NYSE:SYK) by 0.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 22,705 shares of the medical technology company’s stock after selling 184 shares during the quarter. Stryker accounts for approximately 3.5% of GPM Growth Investors Inc.’s holdings, making the stock its 11th biggest holding. GPM Growth Investors Inc.’s holdings in Stryker were worth $8,175,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Moloney Securities Asset Management LLC acquired a new position in Stryker during the 3rd quarter valued at about $1,133,000. Marks Group Wealth Management Inc raised its holdings in Stryker by 3.2% during the 3rd quarter. Marks Group Wealth Management Inc now owns 52,936 shares of the medical technology company’s stock worth $19,124,000 after buying an additional 1,623 shares during the period. Catalina Capital Group LLC raised its holdings in Stryker by 21.1% during the 3rd quarter. Catalina Capital Group LLC now owns 2,005 shares of the medical technology company’s stock worth $724,000 after buying an additional 349 shares during the period. Wisconsin Capital Management LLC grew its stake in shares of Stryker by 6.2% during the 3rd quarter. Wisconsin Capital Management LLC now owns 1,380 shares of the medical technology company’s stock worth $499,000 after acquiring an additional 80 shares in the last quarter. Finally, Radnor Capital Management LLC bought a new position in shares of Stryker during the 3rd quarter worth approximately $4,623,000. Institutional investors own 77.09% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on SYK. Truist Financial raised their target price on shares of Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a research note on Thursday, January 30th. Argus set a $450.00 target price on Stryker in a report on Monday, February 3rd. Wells Fargo & Company lifted their target price on Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. JPMorgan Chase & Co. boosted their price target on Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. Finally, StockNews.com cut Stryker from a “buy” rating to a “hold” rating in a research report on Thursday. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, Stryker has an average rating of “Moderate Buy” and an average price target of $422.15.

Stryker Stock Performance

Shares of SYK stock opened at $396.10 on Thursday. The business’s 50 day simple moving average is $381.96 and its 200 day simple moving average is $372.45. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The stock has a market capitalization of $151.14 billion, a PE ratio of 51.04, a PEG ratio of 2.93 and a beta of 0.96. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the firm earned $3.46 EPS. As a group, research analysts forecast that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.85%. The ex-dividend date is Monday, March 31st. Stryker’s payout ratio is 43.30%.

Insider Transactions at Stryker

In related news, Director Allan C. Golston sold 2,458 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.